A pipeline built on the right Patient × Target × Modality fit

IN-2501 is a tumor-selective ion transporter in MSS colorectal cancer, addressable by ADC or functional antibody to drive targeted killing or disrupt oncogenic signaling. It fuels proliferation, EMT, and metastatic spread, with expression concentrated in metastatic MSS CRC and enriched in CMS2 and CMS4 subgroups.

Therapeutic Opportunity: MSS CRC remains refractory, and IN-2501 offers a biomarker-defined entry point with two mechanistically independent modalities. Independently published preclinical studies document anti-tumor activity for both. No competitive antibody programs are publicly disclosed.

IN-2503 is a tumor-selective cell-surface anchor in MSS colorectal cancer, addressable by blocking antibody, ADC, or bispecific to drive targeted killing or immune cell recruitment. It acts as a dual-function driver: enzymatic survival signaling sustains a stem-cell-like program, while microenvironment interactions and oncogenic signaling facilitate metastasis and immune exclusion.

Therapeutic Opportunity: Immune exclusion is a key reason MSS CRC remains refractory to immunotherapy. Inhibition of IN-2503 restores immune infiltration and resensitizes tumors, positioning it as a biomarker-driven, first-in-class opportunity for next-generation combinations. No competitive antibody programs are publicly disclosed.

The Group of IN-2504 to IN-2517 is a pool of 14 biologic targets in colorectal cancer, selected for tumor-versus-normal differential expression, accessible extracellular architectures, and credible disease biology. Each target is enriched in clinically relevant CRC subgroups, including metastatic subsets, genomic markers, and consensuous molecular subtypes (CMS) classes. More than 50 epitopes across the set span multiple membrane architectures and functional classes, supporting antibody-based and targeted modality options with room for differentiated positioning.

With multiple monoclonal antibodies per epitope in hand, these targets are now in late-stage validation, where patient tissues and patient-derived cellular models resolve responding subgroups, confirm modality fit, and triage candidates for lead development.

The Group of IN-2518 to IN-2527 is a pool of 10 biologic targets in colorectal cancer, selected under the same criteria as IN-2504 to IN-2517. More than 40 epitopes across the set span a broad range of membrane architectures and functional classes, opening antibody-based, ADC, and immune-engaging modality options.

These targets are now in early-stage validation, where Indivumed's platform confirms expression and surface accessibility in patient-derived cellular models and guides antibody generation and modality selection.

Essential in the development and progression of various cancers through regulation of gene expression and cellular behavior, the target is a member of the RNA-helicase family and highly relevant for metastatic CRC.